ACCC questions role of Pfizer’s atorvastatin rebate scheme

Community pharmacy rebates worth around $35.6 million are at the centre of the Australian Competition and Consumer Commission’s (ACCC) case against Pfizer, the commissions’ statement of claim reveals.

The ACCC initiated proceedings against the manufacturer in the Federal Court last week, as previously reported by Pharmacy News, claiming Pfizer had engaged in conduct contravening two sections of the Competition and Consumer Act 2010 (Cth) (CCA).

According to the ACCC statement of claim, Pfizer engaged in conduct contravening Section 46 of the CCA for “purposes that included the substantial